YOR022C Antibody

What is YOR022C protein and what is its primary function in yeast cells?

YOR022C (also known by its gene symbol DDL1) is a unique intracellular phospholipase A1 (iPLA1)-like protein found in the budding yeast Saccharomyces cerevisiae. Unlike its mammalian counterparts, YOR022C functions as a true phospholipase with sn-1-specific activity. Mass spectrometry analysis has definitively demonstrated that YOR022C acts on phosphatidylcholine, phosphatidylethanolamine, and phosphatidic acid, generating 2-acyl lysophospholipids through its enzymatic activity . The protein localizes specifically to the mitochondrial matrix, as confirmed through both fluorescence microscopy with GFP-fused YOR022C (co-staining with MitoTracker) and biochemical fractionation experiments combined with protease sensitivity assays . This mitochondrial localization distinguishes it from mammalian iPLA1 enzymes. YOR022C is the first identified PLA1 that is putatively involved in maintaining sn-1 acyl chains of phospholipids in the mitochondrial inner membrane, suggesting a crucial role in mitochondrial membrane homeostasis and phospholipid metabolism .

How does YOR022C antibody recognize its target, and what epitopes does it bind to?

The YOR022C antibody (CSB-PA613207XA01SVG-0.2) is a rabbit polyclonal antibody that has been raised against recombinant Saccharomyces cerevisiae (strain ATCC 204508/S288c) YOR022C protein . As a polyclonal antibody, it recognizes multiple epitopes on the target protein rather than a single epitope. The antibody is purified through antigen affinity methods, which enhances its specificity for the YOR022C protein . While the exact epitopes have not been fully mapped in the available literature, the antibody's production against the full recombinant protein suggests broad epitope recognition across the YOR022C structure. The polyclonal nature of this antibody makes it particularly valuable for applications requiring robust recognition of the target protein, even under various experimental conditions that might alter protein conformation. Researchers should note that epitope accessibility may differ between applications like Western Blotting (where proteins are denatured) versus ELISA (where proteins may retain native conformation) .

What are the validated applications for YOR022C antibody, and what controls should be included?

The YOR022C antibody (CSB-PA613207XA01SVG-0.2) has been validated for Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blotting (WB) applications . For rigorous experimental design, proper controls are essential. The antibody is provided with 200μg of antigens that can serve as positive controls and 1ml of pre-immune serum that functions as a negative control . For Western Blotting applications, researchers should implement a multi-tiered control strategy: (1) Include a positive control using purified recombinant YOR022C protein; (2) Utilize pre-immune serum as a negative control to assess non-specific binding; (3) Compare wild-type yeast extracts with YOR022C knockout strains to confirm specificity; and (4) Consider performing peptide competition assays to validate antibody specificity. For ELISA applications, similar controls should be employed, with the addition of standard curves using recombinant protein. When designing experiments, it is advisable to optimize antibody concentration through titration experiments, as the optimal concentration may vary depending on the specific experimental conditions and sample types. The manufacturer's recommended storage conditions (-20°C or -80°C) should be strictly followed to maintain antibody functionality .

How can YOR022C antibody be used to study mitochondrial membrane dynamics and cardiolipin remodeling?

YOR022C antibody serves as a powerful tool for investigating mitochondrial membrane dynamics and cardiolipin remodeling due to the protein's localization to the mitochondrial matrix and its phospholipase activity. To study these processes, researchers can employ a multi-methodological approach. First, immunofluorescence microscopy combining YOR022C antibody with mitochondrial markers like MitoTracker can visualize the protein's localization under various experimental conditions . For more detailed subcellular localization, immunoelectron microscopy can be performed using the YOR022C antibody with gold-conjugated secondary antibodies. To investigate YOR022C's role in cardiolipin remodeling, researchers can conduct comparative studies between wild-type and YOR022C knockout strains, analyzing mitochondrial membrane composition through lipidomic analysis. Recent research indicates that cardiolipin remodeling is crucial for maintaining inner mitochondrial membrane integrity, particularly in cells with saturated lipidomes . Experiments can be designed to examine how YOR022C activity correlates with changes in membrane composition under different growth conditions (aerobic versus microaerobic) . For these studies, cells should be grown according to established protocols—for aerobic conditions: overnight growth at 30°C in CSM synthetic media with 2% glucose, followed by backdilution into fresh CSM and growth until stationary phase; for microaerobic conditions: after aerobic pre-incubation, backdilution 1:25 into 24mL fresh CSM media in elongated glass culture tubes with rubber stopper caps, followed by 48-hour incubation at 30°C without shaking .

What are the recommended protocols for using YOR022C antibody in Western blotting of mitochondrial fractions?

When using YOR022C antibody for Western blotting of mitochondrial fractions, researchers should follow a specialized protocol that accounts for the unique properties of mitochondrial proteins. Begin with careful mitochondrial isolation using differential centrifugation or commercially available kits specific for yeast mitochondria. The isolated mitochondria should be lysed in a buffer containing 1% digitonin or Triton X-100, supplemented with protease inhibitors to prevent protein degradation. For optimal results, load 20-40μg of mitochondrial proteins per lane on SDS-PAGE gels (10-12% acrylamide concentration). After separation, proteins should be transferred to PVDF membranes (preferred over nitrocellulose for mitochondrial proteins) using a wet transfer system at 30V overnight at 4°C to ensure complete transfer of hydrophobic proteins. Blocking should be performed with 5% non-fat dry milk in TBST for 1 hour at room temperature. The YOR022C antibody should be diluted (typically 1:1000 to 1:2000, though optimization may be necessary) in TBST with 1% BSA and incubated overnight at 4°C. After washing with TBST (4 times, 5 minutes each), incubate with HRP-conjugated anti-rabbit secondary antibody (1:5000 dilution) for 1 hour at room temperature. Following additional washing steps, develop using enhanced chemiluminescence (ECL) reagents. To verify specificity, parallel experiments should be conducted using the pre-immune serum provided with the antibody kit . For experiments requiring multiple mitochondrial protein detection, stripping and reprobing protocols can be employed, though researchers should be aware that this might reduce signal intensity in subsequent detections.

How can YOR022C antibody be used to investigate the role of phospholipase A1 in hereditary spastic paraplegia models?

YOR022C antibody offers a sophisticated approach to investigating phospholipase A1's role in hereditary spastic paraplegia (HSP) models through its homology with human DDHD1 and DDHD2 proteins . A comprehensive experimental strategy would begin with creating yeast models expressing human DDHD mutations associated with HSP. Researchers can use YOR022C antibody in comparative immunoprecipitation assays to isolate protein complexes from wild-type yeast, YOR022C knockout strains, and strains expressing mutant human DDHD proteins. The precipitated complexes can be analyzed using mass spectrometry to identify differential interaction partners, potentially revealing mechanisms disrupted in disease states. Additionally, YOR022C antibody can be employed in activity assays to measure phospholipase activity in these various strains, correlating enzyme function with phenotypic outcomes. For in-depth structural analysis, researchers should consider using the antibody to purify native YOR022C protein for crystallography studies, comparing wild-type structures with disease-relevant mutations. To establish functional connections between yeast and human systems, complementation studies are essential—human DDHD proteins can be expressed in YOR022C knockout yeast, followed by antibody-based detection methods to assess localization and function. This approach helps determine whether human proteins can rescue phenotypes in the yeast model, validating the relevance of findings to human disease. Throughout these experiments, electron microscopy of mitochondria should be performed to correlate molecular findings with ultrastructural changes, using established fixation protocols (3% glutaraldehyde for 1 hour at room temperature, followed by overnight fixation at 4°C, and zymolyase treatment) .

What experimental approaches can differentiate between the functions of YOR022C and other phospholipases in yeast?

Distinguishing the specific functions of YOR022C from other phospholipases in yeast requires sophisticated experimental approaches leveraging the YOR022C antibody. A comprehensive strategy would combine genetic, biochemical, and imaging techniques. First, researchers should create single and combinatorial knockout strains of different phospholipases, followed by phenotypic characterization under various growth conditions, particularly focusing on mitochondrial function through respiration assays and membrane potential measurements. YOR022C antibody can then be used in Western blotting to confirm knockout efficiency and to check for compensatory upregulation of other phospholipases. For precise functional differentiation, in vitro enzyme assays using purified phospholipases with various phospholipid substrates (phosphatidylcholine, phosphatidylethanolamine, and phosphatidic acid) can determine substrate specificity profiles, with products analyzed by mass spectrometry . Researchers should pay particular attention to the positional specificity of cleavage (sn-1 versus sn-2 positions). Another powerful approach is to use YOR022C antibody in ChIP-seq experiments to identify potential transcriptional feedback mechanisms regulating phospholipase expression. For subcellular localization studies, super-resolution microscopy with YOR022C antibody co-stained with markers for different organelles can precisely map the distribution of various phospholipases. Finally, lipidomic analysis of membrane fractions from different organelles in wild-type versus phospholipase mutants can identify the specific lipid species affected by each enzyme. This multi-faceted approach will provide a comprehensive view of the unique functions of YOR022C compared to other phospholipases in yeast.

How can YOR022C antibody be used to study the relationship between mitochondrial phospholipase activity and respiratory growth?

Investigating the relationship between YOR022C phospholipase activity and respiratory growth requires sophisticated experimental design centered around the YOR022C antibody. Research has indicated that mutants deficient in mitochondrial phospholipase A1 exhibit respiratory growth defects that can be suppressed by overexpression of genes involved in coenzyme Q synthesis . To explore this relationship, researchers should establish parallel cultures of wild-type and YOR022C knockout yeast under both fermentative (glucose-rich) and respiratory (glycerol or ethanol as carbon source) conditions. YOR022C antibody can be used in quantitative Western blotting to measure protein expression levels across these conditions, correlating expression with growth rates and oxygen consumption. For more mechanistic insights, immunoprecipitation with YOR022C antibody followed by activity assays can determine how enzymatic activity changes under different metabolic states. Additionally, researchers should employ the antibody in proximity labeling experiments (BioID or APEX) to identify protein interaction partners specific to respiratory versus fermentative growth, potentially uncovering regulatory mechanisms. To directly link phospholipase activity with respiratory chain function, researchers can perform blue native PAGE of mitochondrial complexes followed by Western blotting with YOR022C antibody to detect potential associations with respiratory complexes. For in vivo monitoring, researchers can create yeast strains expressing fluorescently-tagged YOR022C and use live-cell imaging to track its localization and abundance during metabolic shifts. Finally, lipidomic analysis of mitochondrial membranes under different growth conditions, correlated with YOR022C expression levels (detected by the antibody), can establish direct links between specific lipid species, phospholipase activity, and respiratory capacity.

What are the most common issues when using YOR022C antibody in immunofluorescence, and how can they be resolved?

When working with YOR022C antibody in immunofluorescence applications, researchers commonly encounter several technical challenges. First, high background fluorescence may occur due to non-specific binding. This can be minimized by implementing a more stringent blocking protocol using 5% BSA with 0.3% Triton X-100 in PBS for 2 hours at room temperature, followed by overnight antibody incubation at 4°C with lower concentration (1:500 to 1:1000). Another common issue is weak or absent signal despite confirmed YOR022C expression. This may result from poor epitope accessibility in fixed samples, which can be addressed by testing different fixation methods—comparing 4% paraformaldehyde (10 minutes), methanol (-20°C, 5 minutes), and acetone (-20°C, 5 minutes) to determine optimal epitope preservation. For yeast cells specifically, additional permeabilization with zymolyase treatment (1mg/mL for 30 minutes at 30°C) before antibody incubation can significantly improve antibody penetration . Researchers may also encounter mitochondrial morphology artifacts that complicate co-localization studies. To address this, optimize fixation timing to minimize extraction effects, and consider using live-cell imaging with fluorescently-tagged YOR022C for validation. Signal variability between experiments is another common challenge, which can be mitigated by establishing standard curves with control samples in each experimental batch and normalizing to total protein or a mitochondrial marker like Tom20. Finally, for multi-color immunofluorescence, spectral overlap may create false co-localization signals. This can be resolved by performing proper controls with individual fluorophores and using spectral unmixing during image analysis.

How should researchers interpret conflicting results between YOR022C antibody detection and functional assays?

When researchers encounter discrepancies between YOR022C antibody detection results and functional assays, a systematic troubleshooting approach is essential. First, verify antibody specificity through Western blot analysis using both wild-type and YOR022C knockout controls to confirm the antibody is detecting the correct protein. If antibody detection shows YOR022C presence but functional assays indicate absence of phospholipase activity, consider post-translational modifications or inhibitory factors that might be affecting protein function but not antibody recognition. Perform immunoprecipitation using the YOR022C antibody followed by mass spectrometry to identify potential modifications. Alternatively, if functional assays show phospholipase activity but antibody detection is negative, epitope masking due to protein-protein interactions or conformational changes may be occurring. In this case, try alternative antibody dilutions or different epitope-targeting antibodies if available. Environmental factors such as pH, temperature, or ion concentrations may also differentially affect antibody binding and enzymatic activity. Systematic variation of these conditions in parallel experiments can identify such dependencies. Consider that subcellular compartmentalization might concentrate YOR022C in specific locations, resulting in activity detection despite low total protein levels. In this case, subcellular fractionation followed by Western blotting and activity assays on each fraction can resolve the discrepancy. Lastly, genetic variations or alternative splicing in the yeast strain used might affect either antibody binding or protein function. Sequence verification of the YOR022C gene in the experimental strain compared to the reference strain (ATCC 204508/S288c) used for antibody generation can identify such variations .

What factors influence YOR022C antibody sensitivity and specificity in different experimental contexts?

Multiple factors can significantly impact YOR022C antibody performance across different experimental contexts. Sample preparation methods substantially influence antibody accessibility to epitopes—in membrane-associated proteins like YOR022C, detergent selection is critical. For membrane fractions, digitonin (0.5-1%) preserves membrane protein complexes better than harsher detergents like SDS, which may increase sensitivity but reduce specificity by exposing cross-reactive epitopes. Buffer composition also affects antibody-antigen interactions, with ionic strength modulating electrostatic interactions—typically, 150mM NaCl provides optimal conditions, but optimization may be necessary for specific applications. The presence of phospholipids in samples can compete with antibody binding due to YOR022C's phospholipase function; therefore, lipid removal steps may enhance detection sensitivity in certain contexts. Additionally, post-translational modifications of YOR022C, including phosphorylation, acetylation, or ubiquitination, may mask epitopes or create new ones, altering antibody recognition patterns across different cellular conditions. Temperature and incubation time significantly impact binding kinetics—while standard protocols suggest 1-2 hour incubations at room temperature or overnight at 4°C, specific experimental demands may require optimization. Cross-reactivity with other phospholipases containing similar structural motifs remains a concern, particularly in complex samples. To address this, pre-absorption of the antibody with recombinant related phospholipases can enhance specificity. Finally, the age and storage conditions of the antibody preparation directly affect its performance. Researchers should aliquot antibodies upon receipt and store at -20°C or -80°C to prevent freeze-thaw cycles, which can significantly degrade antibody quality over time .

How should researchers design experiments to investigate YOR022C's role in cardiolipin remodeling under different growth conditions?

Investigating YOR022C's role in cardiolipin remodeling requires carefully designed experiments accounting for both growth conditions and analytical methods. Researchers should establish parallel cultures of wild-type yeast and YOR022C knockout strains under both aerobic and microaerobic conditions following established protocols: for aerobic growth, incubate overnight at 30°C in CSM synthetic media with 2% glucose using culture tubes with snap/vent caps (200 rpm), then backdilute into fresh CSM and grow until stationary phase; for microaerobic growth, after aerobic pre-incubation, backdilute 1:25 into 24mL fresh CSM in elongated glass tubes fitted with rubber stopper caps and grow without shaking for 48 hours at 30°C . At defined time points (24 hours for aerobic, 48 hours for microaerobic), harvest cells for multiple analyses. Use YOR022C antibody for Western blotting to confirm protein expression under different conditions. For microscopic analysis, prepare cells in 8-well coverglass-bottom chambers and perform immunofluorescence with YOR022C antibody co-stained with cardiolipin-specific dyes like nonyl acridine orange. For electron microscopy, fix cells in 3% glutaraldehyde for 1 hour at room temperature followed by overnight fixation at 4°C, treat with zymolyase, and process for TEM imaging . Lipidomic analysis should be performed on isolated mitochondria from each condition to quantify cardiolipin species and their remodeling intermediates. To directly link YOR022C activity to cardiolipin remodeling, conduct in vitro activity assays using immunoprecipitated YOR022C (using the antibody) with different cardiolipin precursors as substrates. Finally, assess mitochondrial function through oxygen consumption measurements, membrane potential assays, and respiratory complex activity to correlate lipid changes with functional outcomes.

How can researchers use quantitative approaches with YOR022C antibody to correlate protein levels with phenotypic outcomes?

Implementing quantitative approaches with YOR022C antibody enables robust correlation between protein levels and phenotypic outcomes. Researchers should begin with quantitative Western blotting using a standard curve of recombinant YOR022C protein at known concentrations (1-100ng range) alongside experimental samples. This calibration allows accurate protein quantification across different conditions and genetic backgrounds. Signal detection should use fluorescent secondary antibodies rather than chemiluminescence for wider linear dynamic range, with internal loading controls (like Tom20 for mitochondrial normalization) included in multiplexed detection schemes. For high-throughput analysis, researchers can employ antibody-based ELISA assays with the YOR022C antibody to quantify protein levels across numerous samples simultaneously, with standard curves on each plate to account for inter-assay variation. Flow cytometry with permeabilized cells stained with YOR022C antibody provides single-cell resolution of protein expression, allowing correlation with individual cell phenotypes like mitochondrial membrane potential (using TMRE dye) or reactive oxygen species (using CellROX). For spatial quantification, quantitative immunofluorescence using confocal microscopy with consistent acquisition parameters can measure regional variations in YOR022C distribution. These protein measurements should be systematically correlated with multiple phenotypic readouts, including growth rates in different carbon sources, oxygen consumption rates, cardiolipin profiles determined by mass spectrometry, mitochondrial morphology quantified by stereological approaches in electron micrographs, and mitochondrial network characteristics assessed by live-cell imaging. Statistical approaches like regression analysis, principal component analysis, and machine learning algorithms can then be applied to these multidimensional datasets to identify significant correlations and potential causal relationships between YOR022C levels and specific phenotypic outcomes.

What emerging technologies could enhance the utility of YOR022C antibody in phospholipid metabolism research?

Emerging technologies offer significant potential to expand YOR022C antibody applications in phospholipid metabolism research. Proximity labeling techniques like BioID or APEX2 can be combined with YOR022C antibody validation to create comprehensive interaction maps under various metabolic conditions. By fusing these enzymatic tags to YOR022C, researchers can identify proximal proteins in living cells, followed by antibody confirmation of interactions. Super-resolution microscopy techniques (STORM, PALM, or STED) coupled with YOR022C antibody staining can provide unprecedented spatial resolution (10-20nm) of the protein's distribution within the mitochondrial matrix, potentially revealing functional microdomains. For temporal dynamics, optogenetic control of YOR022C expression or activity, combined with antibody-based quantification, would allow precise manipulation of phospholipase activity and real-time monitoring of membrane consequences. Mass spectrometry imaging (MSI) overlaid with YOR022C immunofluorescence could create spatially-resolved maps correlating protein localization with specific phospholipid distributions. CRISPR-based approaches also offer exciting possibilities—CRISPRi/CRISPRa systems could enable tunable modulation of YOR022C expression, while CRISPR-mediated tagging could facilitate live cell studies, both validated by antibody detection. Single-molecule tracking using quantum dot-conjugated YOR022C antibody fragments could reveal protein movement dynamics within mitochondria. For high-throughput applications, microfluidic devices integrated with on-chip immunoassays using the YOR022C antibody would enable rapid screening of genetic or chemical perturbations affecting phospholipase function. Finally, computational approaches like molecular dynamics simulations of YOR022C-lipid interactions, informed by antibody-based structural studies, could predict functional consequences of mutations or post-translational modifications, generating testable hypotheses for experimental validation with the YOR022C antibody.

How might comparative studies between yeast YOR022C and human DDHD proteins advance our understanding of hereditary spastic paraplegias?

Comparative studies between yeast YOR022C and human DDHD proteins represent a powerful approach to understanding hereditary spastic paraplegias (HSPs). A comprehensive research strategy would begin with structural comparison—using YOR022C antibody to purify the native yeast protein for structural studies via cryo-EM or X-ray crystallography, comparing these structures with human DDHD proteins to identify conserved catalytic domains and divergent regulatory regions. This structural foundation can guide the design of chimeric proteins containing domains from both yeast and human proteins, followed by functional complementation assays in both yeast and mammalian models, with antibody-based detection confirming expression and localization. Advanced techniques like hydrogen-deuterium exchange mass spectrometry (HDX-MS) coupled with immunoprecipitation using the YOR022C antibody could reveal dynamic structural changes upon substrate binding or regulatory interactions. For pathogenic mechanisms, researchers should create yeast models expressing DDHD mutations identified in HSP patients, using YOR022C antibody to confirm expression levels while examining effects on phospholipid metabolism, mitochondrial function, and cellular health. Comparative phospholipidomics between wild-type and mutant strains can identify specific lipid species affected by the mutations. Since mitochondrial dynamics appear central to HSP pathogenesis, high-content screening using YOR022C antibody staining could evaluate how various HSP-associated mutations affect mitochondrial morphology, membrane potential, and quality control processes. The translational potential of these studies is significant—pharmacological screening could identify compounds that restore function to mutant phospholipases, with efficacy assessed by both enzymatic activity and restoration of normal lipid profiles. Ultimately, insights from these comparative studies could lead to targeted therapeutic approaches for HSPs, potentially extending to other neurodegenerative disorders involving lipid metabolism .

What novel approaches could integrate YOR022C antibody studies with systems biology to understand mitochondrial membrane homeostasis?

Integrating YOR022C antibody studies with systems biology approaches can transform our understanding of mitochondrial membrane homeostasis. A comprehensive systems-level investigation would begin with multi-omics integration—combining antibody-based proteomics, lipidomics, and transcriptomics data from wild-type and YOR022C mutant cells under various conditions. Specifically, researchers should perform immunoprecipitation using YOR022C antibody followed by mass spectrometry to identify the complete interactome, correlating these interactions with changes in the mitochondrial lipidome and transcriptional responses. Network analysis algorithms can then identify key nodes connecting YOR022C activity to broader cellular processes. For dynamic understanding, researchers should implement time-resolved studies using microfluidic devices that enable rapid environmental shifts while monitoring YOR022C levels via automated immunofluorescence, correlating temporal changes in protein expression with mitochondrial membrane fluidity and functionality. Metabolic flux analysis using stable isotope-labeled phospholipid precursors, combined with YOR022C activity measurements via antibody-based enzyme assays, can quantify how phospholipase activity influences membrane turnover rates. To examine cross-organelle communication, proximity labeling of YOR022C combined with antibody validation can identify contact points between mitochondria and other organelles like the ER, potentially revealing how phospholipid transfer occurs between membrane systems. For systematic phenotypic analysis, high-content imaging with YOR022C antibody staining across genome-wide yeast deletion libraries can identify genetic interactions affecting mitochondrial phospholipid homeostasis. Computational modeling represents another frontier—constraint-based modeling of phospholipid metabolism, parameterized with experimental data from YOR022C antibody studies, can predict how perturbations in phospholipase activity propagate through the lipid metabolic network. Finally, evolutionary systems biology comparing YOR022C function across fungal species can reveal how phospholipase-mediated membrane homeostasis has adapted to different ecological niches, providing insights into fundamental principles of mitochondrial membrane regulation .